Jonathan Young - Jan 3, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Stock symbol
AKRO
Transactions as of
Jan 3, 2023
Transactions value $
-$474,163
Form type
4
Date filed
1/5/2023, 04:56 PM
Previous filing
Dec 28, 2022
Next filing
Mar 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $5.4K +8.78K +4.75% $0.62* 194K Jan 3, 2023 Direct F1, F2
transaction AKRO Common Stock Sale -$480K -8.78K -4.53% $54.64 185K Jan 3, 2023 Direct F1, F2, F3
holding AKRO Common Stock 20K Jan 3, 2023 By EA Irrevocable Trust F4
holding AKRO Common Stock 20K Jan 3, 2023 By CM Irrevocable Trust F4
holding AKRO Common Stock 20K Jan 3, 2023 By JL Irrevocable Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Employee Stock Option (Right to Buy) Options Exercise $0 -8.78K -9.53% $0.00 83.3K Jan 3, 2023 Common Stock 8.78K $0.62 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated June 9, 2021, previously adopted by the reporting person.
F2 Includes 2,462 shares that were acquired on December 30, 2022 pursuant to the Akero Therapeutics, Inc. 2019 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $54.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4.
F4 These shares are held in irrevocable trusts for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F5 The options are vested and currently exercisable.